The stock of Spero Therapeutics Inc (NASDAQ: SPRO) has decreased by -6.19 when compared to last closing price of 0.80.Despite this, the company has seen a loss of -13.68% in its stock price over the last five trading days. seekingalpha.com reported 2025-01-19 that Spero Therapeutics’ tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem’s success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM.
Is It Worth Investing in Spero Therapeutics Inc (NASDAQ: SPRO) Right Now?
Spero Therapeutics Inc (NASDAQ: SPRO) has a higher price-to-earnings ratio of 9.49x compared to its average ratio. SPRO has 36-month beta value of 0.68. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for SPRO is 39.50M, and currently, short sellers hold a 0.90% ratio of that float. The average trading volume of SPRO on February 05, 2025 was 241.82K shares.
SPRO’s Market Performance
SPRO’s stock has seen a -13.68% decrease for the week, with a -30.26% drop in the past month and a -38.76% fall in the past quarter. The volatility ratio for the week is 5.77%, and the volatility levels for the past 30 days are at 6.98% for Spero Therapeutics Inc The simple moving average for the past 20 days is -16.58% for SPRO’s stock, with a -41.04% simple moving average for the past 200 days.
Analysts’ Opinion of SPRO
Many brokerage firms have already submitted their reports for SPRO stocks, with Evercore ISI repeating the rating for SPRO by listing it as a “In-line.” The predicted price for SPRO in the upcoming period, according to Evercore ISI is $5 based on the research report published on December 20, 2024 of the previous year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see SPRO reach a price target of $8, previously predicting the price at $2. The rating they have provided for SPRO stocks is “Outperform” according to the report published on September 23rd, 2022.
SPRO Trading at -25.71% from the 50-Day Moving Average
After a stumble in the market that brought SPRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.15% of loss for the given period.
Volatility was left at 6.98%, however, over the last 30 days, the volatility rate increased by 5.77%, as shares sank -31.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.07% lower at present.
During the last 5 trading sessions, SPRO fell by -13.68%, which changed the moving average for the period of 200-days by -49.79% in comparison to the 20-day moving average, which settled at $0.9029. In addition, Spero Therapeutics Inc saw -26.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRO starting from Rajavelu Esther, who sale 23,351 shares at the price of $1.31 back on Nov 07 ’24. After this action, Rajavelu Esther now owns 396,515 shares of Spero Therapeutics Inc, valued at $30,590 using the latest closing price.
Rajavelu Esther, the CFO & CBO of Spero Therapeutics Inc, sale 17,245 shares at $1.30 during a trade that took place back on Nov 08 ’24, which means that Rajavelu Esther is holding 379,270 shares at $22,418 based on the most recent closing price.
Stock Fundamentals for SPRO
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 1.12 for the gross margin
The net margin for Spero Therapeutics Inc stands at 0.03. The total capital return value is set at -0.09. Equity return is now at value 5.90, with 2.90 for asset returns.
Based on Spero Therapeutics Inc (SPRO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.79. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -8.18.
Currently, EBITDA for the company is 25.77 million with net debt to EBITDA at 73.71. When we switch over and look at the enterprise to sales, we see a ratio of -0.34. The receivables turnover for the company is 1.69for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.68.
Conclusion
To put it simply, Spero Therapeutics Inc (SPRO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
